ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1133

Patient Perceptions of Diagnosis, Tests, Treatments, Adherence and the Impact on Their Disease Understanding and Participation in Research Studies

Viviana Marzaioli1, Mary Canavan1, Siobhan Wade2, Alexander Fraser3, Sinead Harney4, Alex Donnelly5, Arthritis Ireland Charity6, Douglas Veale7 and Ursula Fearon1, 1Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, 2Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, 3University College Limerick, Limerick, Limerick, Ireland, 4University College Cork, Cork, Ireland, 5Patient Advocate Arthritis Ireland, Dublin, Ireland, 6Arthritis Ireland, Dublin, Ireland, 7EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, education, patient, health behaviors, Inflammation, pregnancy

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The diagnosis and treatment of inflammatory arthritis has been transformed largely by  the development of drugs that target specific molecules of the immune system. However, these changes have increased the complexity of the mechanisms of disease, its treatment and patients understanding. Patient education is needed in this area to facilitate decision making.

Methods: An online anonymous survey of 27 questions addressed patient understanding of their diagnosis, diagnostic tests performed at outpatient clinics, their treatments and how they worked. Questions also addressed adherence and disease flare, issues of heredity and pregnancy, and patient involvement in research.

Results: The survey was completed by 1,873 patients, 1607 had an inflammatory arthritis  RA (62.29%),  SpA (41.88%) and JIA (2.92%). Respondents were predominantly female (83.77%). Most patients understood the difference between inflammatory arthritis and osteoarthritis  (68.12% vs 31.88%), and 76.48% were concerned it was hereditary. Patients were asked to indicate their understanding of diagnostics tests performed at out-patient clinics (Scale 1-10; 1=don’t understand at all, 10=understand very clearly). For all diagnostic tests < 25% of patients had an understanding of what was measured and the implication for disease,  including ESR, CRP, RF, anti-CCP, VAS and Das28.    Significantly, 72% understood how specific medications treat inflammatory arthritis, while 27.97% had no understanding.  Adherence was strong with >87% vs 12% adhering to their medication.  Of those stopping medication, without the advice of their doctor, the main reasons were ‘feeling better’, ‘don’t think it works’ and ‘side effects’, however 68.43% of these patients also reported disease flare following cessation of medication. Patients of childbearing age (31%) worried that inflammatory arthritis reduced their chances of getting pregnant, and 79% believed arthritis medications are not safe to take during pregnancy. Finally,  only 9% of patients had ever been asked to participate in a research study by their doctor.

Conclusion: This patient awareness survey demonstrates that patients have an understanding of their diagnosis, but little understanding of the diagnostic tests performed, their implication for disease progression and response. Furthermore patients concerns regarding heredity and pregnancy need to be addressed more thoroughly. Patients reported significant medication adherence, with those non-adherent experiencing flares. Finally, very few patients had been asked to participate in a research study.


Disclosure: V. Marzaioli, None; M. Canavan, None; S. Wade, None; A. Fraser, None; S. Harney, None; A. Donnelly, None; A. Charity, None; D. Veale, AbbVie, 2, Health Beacon, 1, Janssen, 2, 8, Pfizer, 2, 5, 8, Novartis, 2, 5, 8, UCB, 2, 5; U. Fearon, None.

To cite this abstract in AMA style:

Marzaioli V, Canavan M, Wade S, Fraser A, Harney S, Donnelly A, Charity A, Veale D, Fearon U. Patient Perceptions of Diagnosis, Tests, Treatments, Adherence and the Impact on Their Disease Understanding and Participation in Research Studies [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/patient-perceptions-of-diagnosis-tests-treatments-adherence-and-the-impact-on-their-disease-understanding-and-participation-in-research-studies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-perceptions-of-diagnosis-tests-treatments-adherence-and-the-impact-on-their-disease-understanding-and-participation-in-research-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology